Home/Tessellate BIO/Katie Chapman
KC

Katie Chapman

CSO

Tessellate BIO

Therapeutic Areas

Tessellate BIO Pipeline

DrugIndicationPhase
ALT programCancers with Alternative Lengthening of Telomeres (ALT) mechanismPre-clinical
Loss-of-Function (LoF) programCancers with Retinoblastoma 1 (RB1) Loss-of-FunctionPre-clinical